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TLR4 adjuvantThe development of a chlamydial vaccine that elicits protective mucosal immunity is of paramount
importance in combatting the global spread of sexually transmitted Chlamydia trachomatis (Ct) infections.
While the identification and prioritization of chlamydial antigens is a crucial prerequisite for efficacious
vaccine design, it is likely that novel adjuvant development and selection will also play a pivotal role in
the translational potential of preclinical Ct vaccines. Although the molecular nature of the immuno-
modulatory component is of primary importance, adjuvant formulation and delivery systems may also
govern vaccine efficacy and potency. Our study provides the first preclinical evaluation of recombinant
Ct polymorphic membrane protein D (rPmpD) in combination with three different formulations of a novel
second-generation lipid adjuvant (SLA). SLA was rationally designed in silico by modification of glucopy-
ranosyl lipid adjuvant (GLA), a TLR4 agonistic precursor molecule currently in Phase II clinical develop-
ment. We demonstrate robust protection against intra-vaginal Ct challenge in mice, evidenced by
significantly enhanced resistance to infection and reduction in mean bacterial load. Strikingly, protection
was found to correlate with the presence of robust anti-rPmpD serum and cervico-vaginal IgG titres, even
in the absence of adjuvant-induced Th1-type cellular immune responses elicited by each SLA formulation,
and we further show that anti-rPmpD antibodies recognize Ct EBs. These findings highlight the utility of
SLA and rational molecular design of adjuvants in preclinical Ct vaccine development, but also suggest an
important role for anti-rPmpD antibodies in protection against urogenital Ct infection.
Crown Copyright  2016 Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Chlamydia trachomatis (Ct) is the most common sexually trans-
mitted bacterial pathogen worldwide, responsible for 131 million
new cases of disease each year [1]. Urogenital infections are
asymptomatic in 30–50% of men and 70–90% of women, with
major complications such as pelvic inflammatory disease (PID)
and infertility occurring predominantly in women [2]. Aggressive
‘seek and treat’ public health measures have not stemmed the rise
of infection rates, leading to proposal of the ‘arrested immunity’
hypothesis [3]. This suggests vaccination as a key step in control-ling and potentially eliminating Ct infections [4]. Due to the
paucity of robust clinical data, protective immunological parame-
ters have largely been derived from preclinical murine models.
Ct or the mouse pneumonitis biovar Chlamydia muridarum (Cm)
have been utilised to study chlamydial infections and vaccine effi-
cacy in mice, although neither model mimics all aspects of human
disease and pathogenesis [5]. Several studies investigating protec-
tive immunity and vaccine efficacy have focused on intra-vaginal
Cm challenge which typically results in a more prolific ascending
infection with lower inoculating doses than Ct, that can rapidly
progress to hydrosalpinx and infertility [6]. Thus, the Cm model
may be widely applicable for the study of therapeutic vaccines
against post-infection sequelae, although intra-vaginal infection
with certain Ct serovars can also result in ascending infection [7].
Furthermore, it has been suggested that Ct infection in mice may
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rarely progress so quickly to upper-genital tract pathology [8].
Although a high degree of genomic synteny is apparent, differ-
ences within the plasticity zones of Cm and Ct genomes may influ-
ence infection outcomes in the murine model [9,10]. Cm possesses
three functional paralogous copies of the cytotoxin gene that is
truncated and likely non-functional in the majority of urogenital
Ct serovars [11]. The cytotoxin gene is thought to influence
chlamydial sensitivity to IFNc through targeting of GTPases, and
may differentially mediate innate immune evasion in the host
[12,13]. Such observations have cautionary implications for the
investigation of chlamydial infections in mice, as it has recently
been suggested that innate immunity is sufficient to resolve Ct
but not Cm infection [14]. However, the study also indicates a dual
role for adaptive immunity in reducing Ct bacterial burden and
time to clearance, and vaccine-induced protective immunity has
previously been investigated in mice using Ct as the agent of infec-
tion [15–17].
Subunit vaccines have displaced the use of whole-cell organ-
isms following the incidence of inflammatory reactions in non-
human primates post challenge, although this was found not toFig. 1. rPmpD-specfic cytokine responses following immunization with different vaccin
rPmpD two weeks after the final immunization (A, C, E) or six weeks post-challenge (B, D,
in cytokine profiles are observed. The results are expressed as the mean ± the standard de
**P 6 0:01, ***P 6 0:001 relative to PBS-immunized mice).be the case in humans [18–20]. Hence, identification and prioriti-
zation of novel chlamydial antigens that elicit protective cell-
mediated and/or humoral immunity is of great importance. Recent
studies using Cm have highlighted a promising role for chlamydial
polymorphic membrane proteins (Pmps) as vaccine candidates
[21,22]. However, Pmps E and F are highly polymorphic within
genital Ct strains, and PmpG possesses regulatory sequences
indicative of phase variation, suggesting a role for Pmps in immune
evasion [23]. In contrast, Ct PmpD possesses the highest inter-
strain sequence conservation (>99.15%) among the nine-member
family, implying a conserved role in biphasic development or viru-
lence [24]. Furthermore, PmpD has been implicated in mediating
early host-cell interactions [25,26].
Here, we provide the first preclinical investigation of a candi-
date chlamydial vaccine, evaluating three different formulations
of a rationally designed TLR4 agonistic second-generation lipid
adjuvant (SLA) in combination with Ct rPmpD. SLA was designed
in silico (Carter et al., submitted) through rational modification of
the terminal acyl chains of glucopyranosyl lipid adjuvant (GLA)
[27], a precursor molecule that has demonstrated tolerability and
immunogenicity in Phase 1 trials [28].e formulations in C57BL/6 mice. Splenocytes were harvested and stimulated with
F), and assessed for IFNY, IL-5 or IL-10 secretion. SLA formulation-specific differences
viation for groups of 5 mice measured in triplicate from two experiments (*P 6 0:05,
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tion in C57BL/6 mice, characterized by significantly enhanced
resistance to infection and bacterial clearance. While all SLA
formulations elicited significantly enhanced magnitudes of
rPmpD-specific Th1-biased immune responses that correlated with
resistance to infection and reduced bacterial burden, protection
was also observed following immunization with rPmpD alone in
the absence of SLA-induced Th1-bias, which coincided with robust
anti-rPmpD serum and cervico-vaginal IgG titres. Hence, we pro-
pose that anti-rPmpD antibodies may play a significant role in
vaccine-mediated protection against intra-vaginal Ct challenge,
and demonstrate that SLA represents a novel adjuvant class that
may be more widely utilised in future chlamydial vaccine
development.2. Materials and methods
2.1. Ct cell culture
Ct serovar E/Bour (American Type Culture Collection [ATCC])
and Ct serovar D/UW3/Cx (Prof. Shattock, Imperial College) were
propagated in McCoy cells (ATCC) and purified as described
previously [29].Fig. 2. rPmpD-specific IgG1 and IgG2c responses following immunization with differen
titres were measured two weeks following penultimate and final immunisations (A, C) or
standard deviation for groups of 5 mice measured in triplicate, and are representative o2.2. Preparation of recombinant PmpD and UV-inactivated Ct EB
vaccines
A DNA construct encoding the 65 kDa (aa68-aa698) passenger
domain fragment previously identified by mass spectrometry
following in vitro infection [30] was inserted into the pET 28(b)
vector (Novagen) with a C-terminal hexa-histidine tag. Following
over-expression in E. coli BL21(DE3) strain (Novagen), purification
and refolding was implemented by stepwise dialysis of 6 M guani-
dinium hydrochloride from inclusion bodies, ending up in 20 mM
Tris, 50 mM NaCl (pH 8). This yielded soluble protein that was
purified by metal affinity and size exclusion chromatography. Fol-
lowing 0.1% Triton X-114 extraction of E. coli LPS [31], the Limulus
Amebocyte Lysate test was utilised to determine the amount of
endotoxin in the rPmpD preparation, which was found to be below
1EU/mg. Ct E/Bour elementary bodies were inactivated by UV irra-
diation (UVEB) at a distance of 15 cm from a UV-lamp for 60 min.
2.3. Second-generation lipid adjuvant formulations
Second-generation lipid adjuvant (SLA) was synthesised by Cor-
den Pharma (Liestal, Switzerland). Aqueous formulations (SLA-AF)
were manufactured by mixing SLA with dipalmitoyl phosphatidyl-
choline (DPPC) at a DPPC:SLA molar ratio of 2:1 in chloroform, andt rPmpD vaccine formulations in C57BL/6 mice. Anti-rPmpD serum IgG1 and IgG2c
six weeks post-challenge (B, D). Results are expressed as the geometric mean ± the
f two separate experiments. (*P 6 0:05, **P 6 0:01).
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cated in a 60 C water bath until translucent. Oil-in-water emul-
sions (SLA-SE) were manufactured by high-speed mixing
poloxamer 188, glycerol, and ammonium phosphate buffer with
an oil phase (squalene, dimyristoyl phosphatidylcholine) and SLA.
The liposomal formulation (SLA-LSQ) was mixed with aqueous
QS21 following addition of dioleoyl phosphatidylcholine:choles
terol (4:1 w/w ratio) with SLA in chloroform and hydration in
25 mM ammonium phosphate buffer (pH 5.7) with sonication
to achieve a monodisperse particle size 80 nm.2.4. Mouse immunizations
All animal care and experimental procedures were performed
under UK Home Office License (Ref # PPL 70/7805) and with
approval from the Animal Procedures and Ethics Committee of
the University of York. 6–8 week old female C57BL/6 mice were
bred and maintained under specific pathogen-free conditions at
the University of York, allocated to groups and immunized subcu-
taneously (s.c.) at the base of the tail on days 0, 21 and 42 with
100 ll of sterile PBS containing 5 lg/dose of adjuvant (SLA-AF,
SLA-SE or SLA-LSQ) with 5 lg/dose rPmpD or 2  107 inclusion
forming units (IFU) of UVEBs. Additional groups of mice received
rPmpD, SLA-AF, SLA-SE, SLA-LSQ or PBS alone as controls.2.5. Vaginal Ct challenge and determination of chlamydial load
All animals received a subcutaneous injection of 2.5 mg of
medroxyprogesterone acetate (Depo-Provera, Pfizer) one weekFig. 3. Immunization with rPmpD elicits robust cervico-vaginal antigen-specfic IgG titr
rPmpD IgG1 (A) and IgC2c (B) titres were measured at the indicated time points prior to
immunization prior to Ct challenge. Results are expressed as the geometric mean ± the st
in Fig. 2, and are representative of two separate experiments (*P 6 0:05).prior to challenge. Three weeks after the final vaccination, mice
were challenged intra-vaginally with 107 IFU of Ct serovar
D/UW3/Cx EBs as previously described [7,17]. Cervico-vaginal
swabs were obtained on days 1, 3, 7, 14 and 22 post-challenge,
and the total number of inclusions per well were enumerated in
a blinded fashion using fluorescence microscopy.2.6. Cervico-vaginal washes
Cervico-vaginal washes were obtained on days 34 and 55 post
initial immunization. 100 ll of sterile-filtered PBS were pipetted
up-and-down the vaginal cavity ten times using a Microman Preci-
sion Microliter Pipette with rounded-tip capillary pistons (Gilson).
To prevent protein degradation, 25 Protease Inhibitor Cocktail
(Sigma–Aldrich) was added. Cervico-vaginal washes were stored
at 80 C until use.2.7. Measurement of serum and cervico-vaginal antigen-specific
antibody
Serum was obtained on days 0, 35 and 56 following initial
immunization and 6 weeks post challenge. 96-well Assay plates
(Costar) were coated with 50 ll rPmpD (1 lg/ml) at 4 C overnight
in coating buffer (0.1 M Na2CO3, 0.1 M NaHCO3, pH 9.6). Plates
were washed four times with 300 ll/well wash buffer (1 PBS,
0.05% Tween-20), and all subsequent washing steps carried out
in identical fashion using an automated SkanWasher 400 (Molecu-
lar Devices, USA). Blocking buffer (1 PBS, 0.05% Tween-20, 0.1%
BSA) was added (200 ll/well) and plates incubated for 2hr at roomes. C57BL/6 mice were immunized with all rPmpD formulations and mucosal anti-
Ct challenge. (C) Formulation-specific IgG2c:IgG1 titre ratios two weeks post final
andard deviation for groups of 5 mice measured in triplicate for the same animals as
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well) or cervico-vaginal lavage. After incubation for 2 h at 37 C,
plates were washed and then incubated with HRP-conjugated goat
anti-mouse IgG, IgG1 or IgG2c antibodies (AbD Serotec) at 37 C for
30 minutes. After the final wash step, 50 ll/well of 30,5,50-tetrame
thylbenzidine (TMB) substrate solution (Sigma-Aldrich) was
added. Colour development was stopped after 5 min with 1 M
H2SO4 (KPL, USA) and plates were read immediately at 450 nm
(OD450) with a VersaMax microplate reader in conjunction with
the SoftMax Pro v.5.3 software (Molecular Devices, USA). Recipro-
cal serum dilutions corresponding to 50% maximal binding were
used to obtain titres.2.8. Antigen-specific cellular responses
Animals were euthanized and spleens collected and homoge-
nized into single cell suspensions. Enzyme-linked immunospot
(ELISpot) assays were performed immediately following splenic
harvest. Briefly, 96-well MultiScreen filtration plates (Millipore)
were coated overnight at 4 C with IFNc, IL-5 or IL-10 monoclonal
capture antibodies (Mabtech). Splenocytes (2.5  105 cells/well)
were added to the plate in the presence of 1 lg/ml rPmpD. After
incubation at 37 C with 5% CO2 for 20 h, plates were washed
and incubated with respective biotinylated detection antibodies
according to manufacturer’s protocol (Mabtech). This was followed
by incubation with streptavidin-alkaline phosphatase (1 h, RT) and
addition of BCIP/NBT-plus substrate until distinct spots emerged.
Spot forming units (SFU) were enumerated by eye.Fig. 4. Reactivity of anti-rPmpD and anti-UVEB serum. Serum from mice immunized wit
blots. (C) Anti-rPmpD serum reacts with UVEBs in an indirect ELISA (inset shows reacti
reactivity against UVEBs). Dotted lines represent the OD450 cut-off value equivalent to t2.9. Statistical analysis
Differences between two independent means were determined
with a two-tailed t-test using GraphPad Prism 6. For multiple com-
parisons, groups were compared using a one-way analysis of vari-
ance (ANOVA) following transformation of skewed distributions in
STATA/IC 10 (StataCorp, USA). Sample size calculations were per-
formed in G⁄Power version 3.1 using both a priori analysis based
on previous studies [17,22] and post hoc pilot experiments per-
formed in our laboratory. A total of 5 animals were sufficient to
detect expected effect sizes with a power of 08 (alpha = 005) for
all experimental readouts.3. Results
3.1. SLA in combination with rPmpD induces a robust Th1-type
immune response and significantly enhances systemic and cervico-
vaginal rPmpD-specific IgG titres
To evaluate the immunogenicity of rPmpD adjuvanted with dif-
ferent formulations of SLA, C57BL/6 mice were immunized, and
splenic rPmpD-specific cellular immune responses elicited by each
vaccine formulation were determined using ELISpot both pre- and
post-Ct challenge (Fig. 1A–F). In the absence of adjuvant, immu-
nization with rPmpD elicited a minimal recall IFNc response, with
no detectable significant difference from control groups (Fig. 1A).
However, mice immunized with rPmpD in combination with all
SLA formulations showed significantly elevated antigen-specifich rPmpD (A) or UVEBs (B) was tested for reactivity against each antigen in western
vity against rPmpD). (D) Anti-UVEB serum failed to react with rPmpD (inset shows
he mean plus two standard deviations of control pre-immune serum.
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Formulation-specific differences in the magnitude of the T cell
responses were observed. SLA-SE elicited the most robust IFNc
response following stimulation with rPmpD (>500 spots/250,000
spleen cells), with no significant difference between IFNc levels
in SLA-AF-immunized (76 ± 38 cells/250,000) and SLA-LSQ-
immunized mice (145 ± 81/250,000) detected (p = 0.1739).
Although the rPmpD-specific IL-10 response was significantly aug-
mented with the SLA-SE and SLA-AF formulations (Fig. 1E), the sig-
nificantly enhanced IFNc:IL-10 ratio elicited by the SLA-SE-rPmpD
vaccine clearly indicates that SLA-SE biases towards robust Th1-
type immune responses in vivo. Interestingly, only the SLA-SE-
induced rPmpD-specific IFNc response was significantly boosted
following Ct infection (Fig. 1B).
To assess vaccine-induced humoral immunity, rPmpD-specific
serum IgG responses were measured two weeks following the
penultimate and final boosts (Fig. 2A and C). The reciprocal titres
at 50% maximal binding of anti-rPmpD IgG1 and IgG2c were mea-
sured. No rPmpD-specific IgG was detected in mice immunized
with PBS or SLA alone, while rPmpD administered in the absence
of SLA elicited robust systemic IgG1 humoral immune responses,
but showed no detectable IgG of the 2c subclass pre- or post-
challenge (Fig. 2C and D). As class switching to IgG2c is mediated
by IFNc, these data are consistent with the cytokine results shown
in Fig. 1. All rPmpD-SLA combinations induced robust IgG1 and
IgG2c rPmpD-specific titres, with demonstrable increases in titres
following successive immunizations that also remained elevated
6 weeks post infection with Ct (Fig. 2B and D).
To assess mucosal humoral responses, cervico-vaginal washes
were obtained two weeks following the penultimate and final
immunizations. Consistent with serum IgG subclasses, no
detectable levels of IgG2c were observed in mice immunized withFig. 5. Infection curves showing bacterial shedding following challenge of vaccinated m
weeks post final immunization with either rPmpD or Ct serovar E/Bour UVEBs (positive
recoverable cervico-vaginal IFU assessed on Hak cell monolayers. Culture-negative m
differences in time to complete resolution of infection are observed. Results are expressrPmpD alone. While no significant difference between SLA-AF and
SLA-LSQ-induced cervico-vaginal titres were observed, the SLA-SE
formulation elicited significantly greater anti-rPmpD IgG titres
and IgG2c:IgG1 ratios within the vaginal vault following the final
immunization (Fig. 3), consistent with robust induction of
Th1-type immunity (Fig. 1A).
3.2. Reactivity of anti-rPmpD and anti-UVEB serum in Western Blot
and ELISA
To determine reactivity against both native and non
conformational-dependent epitopes, ELISA and western blotting
were implemented using heat-inactivated serum from rPmpD-
and UVEB-immunized mice two weeks following the final boost,
prior to challenge (Fig. 4). Anti-rPmpD serum from all vaccine
groups reacted strongly with rPmpD in both assays, and cross-
reacted with UVEBs in ELISAs, showing recognition of epitopes
on Ct EBs. Anti-UVEB serum did not cross-react with rPmpD in
ELISA or western blot, but reacted with UVEBs in both assays,
showing immunodominant recognition of Ct major outer mem-
brane protein (MOMP) (Fig. 4B).
3.3. Vaccination with rPmpD in the presence or absence of SLA
significantly enhances resistance to Ct infection and reduces mean
bacterial load
Cervico-vaginal swabs were obtained from all vaccine groups
on days 1, 3, 7, 14 and 22 following intra-vaginal challenge with
Ct serovar D (Fig. 5). For quantification of resistance to infection,
recoverable IFU at day 1 were compared between each group using
a one-way ANOVA (Fig. 6A). Mean bacterial load over time was
quantified using an integrative area under the curve (AUC) methodice. C57BL/6 mice were infected intra-vaginally with Ct serovar D/UW3/Cx three
control). Individuals were swabbed on days 1, 3, 7, 14 and 22 post infection, and
ice were assigned a cut-off value of <10 IFU. Formualtion- and antigen-specific
ed as the mean ± the standard deviation for groups of 5 mice.
Fig. 6. Quantification of vaccine elicited protection against Ct challenge. (A) Resistance to infection was assessed by swabbing individuals on day 1 and determining
recoverable IFU on Hak cell monolayers. (B) Total bacterial load over the 22 day time period was quantified by integrating the area under the shedding curves (depicted in
Fig. 5) for individual mice. Data were analysed using a one-way analysis of variance (ANOVA) for groups of five mice. Significance values displayed are relative to PBS-
immunized mice (*P 6 0:05, **P 6 0:01, ***P 6 0:001).
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resistance to infection and significant reduction in bacterial burden
relative to sham-immunized mice (Fig. 6).
No significant differences in resistance to infection or bacterial
burden between PBS-immunized mice and adjuvant only groups
(SLA-AF, SLA-SE, SLA-LSQ) were observed, suggesting non-specific
innate immune activation by SLA formulations in the absence of
antigen does not play a role in protection. Furthermore, the time
to complete clearance (where all individuals within a group were
culture-negative) for each vaccine antigen was found to be
formulation-dependent, with SLA-SE resulting in the shortest time
to clearance relative to SLA-AF or SLA-LSQ formulations indepen-
dent of antigen (Fig. 5C). Strikingly, rPmpD administered in the
absence of SLA resulted in significantly enhanced resistance to
infection and reduced bacterial load relative to sham-immunized
mice (Fig. 6), although all individuals within this group failed to
completely resolve infection (Fig. 5A). Although no significant dif-
ference in resistance to infection or bacterial load was observed
between rPmpD-SLA vaccine formulations (Fig. 6), the time to
clearance (Fig. 5) and magnitude of Th1 bias (Fig. 1A) were
formulation-dependent. SLA-SE elicited the most robust rPmpD-
specific IFNc recall responses pre- and post-challenge, and resulted
in the shortest time to clearance when coupled with either rPmpD
or UVEBs (Fig. 5).4. Discussion
Our study demonstrates the formulation-specific efficacy of
SLA, a novel TLR4 agonist, at inducing Th1-biased immuneresponses and protection against Ct infection in combination with
rPmpD in vivo. The enhanced magnitude of both innate and adap-
tive cellular responses observed with squalene emulsions (SE) has
previously been associated with inflammasome activation in vivo.
Early IFNc and IL-18 production by neutrophils and memory CD8+
T cells was ablated in caspase-1/11–/– and IL-18 receptor 1–/– mice
following administration of GLA-SE, thus proposing a mechanistic
basis for the observed potency of SLA-SE in our study [32].
Importantly, we also highlight the protective efficacy of rPmpD
against urogenital Ct infection in the absence of adjuvant. A similar
phenomenon has recently been observed where un-adjuvanted
recombinant Ct MOMP elicited comparable antibody responses to
adjuvanted MOMP, which correlated with protection [33]. Robust
pathogen-specific Th1-type immunity is widely regarded as a
robust parameter for screening preclinical chlamydial vaccines
[34], and Stary et al. have recently detailed cell-mediated effector
mechanisms underlying vaccine-induced mucosal immunity
against Ct infections [35]. Unexpectedly, despite the generation
of robust Ct-specific humoral responses, the authors reported no
definitive role for antibody-mediated protection, and detect no sig-
nificant difference in recoverable IFU between immunized and
naïve mice at day 1 post challenge. In contrast, we demonstrate
significantly reduced recoverable IFU on day 1 between rPmpD-
and sham-immunized mice (Fig. 6A).
Although possible vaccine-induced innate effector mechanisms
cannot be ruled out, protection in our study correlates with the
presence of robust pathogen-specific serum and mucosal antibody
titres irrespective of SLA-induced Th1-bias. However, mice immu-
nized with rPmpD alone fail to completely resolve infection at day
22 (Fig. 5A), suggesting that adaptive rPmpD-specific cellular
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ance. Very few studies have highlighted a role for Ct-specific
antibodies in vaccine-mediated protection, although antibody-
mediated protection has previously been described in the Cm
model of infection [36]. Indeed, the only convincing evidence
describing a protective role for anti-Ct antibodies in vivo focuses
on the antigenically variable MOMP antigen, where passive trans-
fer of serum from immunized mice conferred early protection
against infection, suggesting systemic neutralizing antibody is suf-
ficient to mediate lower genital tract protection [37]. Our study
demonstrates the efficacy of subcutaneous vaccination at eliciting
robust antigen-specific mucosal IgG responses, and we further
show that immune serum from rPmpD-immunized mice cross-
reacts with UVEBs in ELISA (Fig. 4C), confirming antibody recogni-
tion of the agent of infection.
Further work is now required to detail the underpinnings of
other likely immuno-modulatory properties of rPmpD. For
instance, the Leishmania major hydrophilic acylated surface protein
B (HASPB) elicited long-term protection and antigen-specific CD8+
T cells in the absence of exogenous adjuvant or delivery vehicle,
where natural antibody binding and complement act as endoge-
nous adjuvants that bridge innate and adaptive immunity [38].
Similarly, the leishmanial vaccine candidate antigen LeIF was
shown to possess inherent IL-12 stimulating capacity [39,40].
A prophylactic chlamydial vaccine that reduces infectious bur-
den or time to clearance is likely to have significant global health-
care benefits. Based on our results and the efficacy of precursor
molecule GLA in clinical trials, we propose that SLA may be incor-
porated as a novel adjuvant in future preclinical chlamydial vacci-
nes with significant translational potential. Furthermore, the high
degree of pan-strain conservation of Ct PmpD and immunodomi-
nance in patient cohorts highlights the potential for eliciting broad
protection against a diverse array of circulating strains [24,41,42].Financial support
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